We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In-vivo Efficacy Profile of Decitabine
News

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In-vivo Efficacy Profile of Decitabine

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In-vivo Efficacy Profile of Decitabine
News

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In-vivo Efficacy Profile of Decitabine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In-vivo Efficacy Profile of Decitabine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SuperGen Inc. has announced as part of a series of presentations at the 2008 AACR Annual Meeting that S-110, its DNA methyltransferase inhibitor, improves in vivo efficacy of decitabine (Abstract No. 2613).

Entitled, "Decitabine administered as a Dinucleotide prodrug increases its in vivo efficacy due to enhanced drug delivery and stability," the poster highlights data indicating that S-110 showed robust anti-tumor activity in prostate and cisplatin-resistant ovarian carcinoma xenograft models. Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancer model. Importantly, reduced toxicity was observed along with an increased half-life compared to decitabine.

"S-110's increased half-life, reduced toxicity and improvement of efficacy when compared to decitabine in its currently marketed formulations make it an attractive, next-generation hypomethylator for the treatment of hematoligic malignancies," said Dr. James Manuso, SuperGen's President and CEO.

Dr. James added, "As we develop S-110 further, we will continue to explore its potential to enhance solid tumors' sensitivity to standard chemotherapy agents, including cisplatin. We look forward to advancing this promising candidate to clinical trials later this year or early next year."

Advertisement